Jeff Vierstra is a man who thrives on the edge. Whether he is skiing down an iceberg off the coast of Chile or skydiving over the rugged landscapes of British Columbia, the 41-year-old scientist is accustomed to calculated risks. But for decades, there was one danger he could not outrun: his own DNA.
Vierstra carries a mutation of the FUS gene, a critical component for normal nerve cell function. In his family, this genetic marker has acted as a relentless clock. His mother died when he was just two years old, and all of her siblings succumbed to Amyotrophic Lateral Sclerosis (ALS) in their late thirties and early forties. Later, his two sisters, Erin and Leigh, too tested positive for the mutation and eventually died from complications of the disease.
Now, Vierstra is the center of a medical milestone. He is participating in what is believed to be the first known attempt to use an experimental treatment to prevent ALS before the full onset of the disease, rather than simply attempting to slow its progression after symptoms appear.
“Living with that sort of like cloud over you is like mentally and emotionally like really difficult,” Vierstra said.
The Genetic Architecture of ALS
ALS, often referred to as Lou Gehrig’s disease, is a devastating neurodegenerative condition characterized by the progressive degeneration of motor neurons. These are the nerve cells responsible for controlling voluntary muscle movement. As these neurons die, patients lose the ability to walk, talk, eat, and eventually, breathe. According to the Centers for Disease Control and Prevention, an estimated 35,000 people in the United States are currently living with the disease.
While most cases are sporadic, roughly 10% to 15% of patients have a genetic form of the disease. Dr. Neil Shneider, a neurologist at Columbia University who specializes in genetic ALS, notes that about two-thirds of these genetic cases are familial, meaning they affect multiple generations of a single family.
The FUS mutation found in Vierstra’s family is particularly aggressive. Due to the fact that the protein encoded by the FUS gene is essential for the health of nerve cells, a mutation can cause the protein to malfunction or clump, leading to the rapid death of motor neurons. For Vierstra, the knowledge of this mutation was not just a medical fact; it was a looming deadline.
Intervening Before the Onset
The turning point for Vierstra came during a series of screenings at the Eleanor and Lou Gehrig ALS Center at Columbia University. While his sisters had already begun developing symptoms and were enrolled in a clinical trial, Vierstra was initially asymptomatic. However, an electromyography (EMG)—a test that measures the electrical activity of muscles—revealed mild abnormalities.
“It was a difficult moment,” Dr. Shneider said. “We thought this meant that this was an early sign of disease onset and that he was at risk for developing full blown disease.”
Rather than waiting for the inevitable decline, Dr. Shneider offered Vierstra the same experimental therapy his sisters were receiving: a series of spinal infusions designed to target and disable the mutated FUS gene. The goal was to “silence” the toxic genetic instructions before they could cause irreversible neuronal death.
“I jumped at the opportunity to do that,” Vierstra said.
For three years, Vierstra has undergone these infusions every few months. The result has been unexpected: after one year of treatment, follow-up muscle testing showed that the previous abnormalities had normalized. While the treatment did not cure his sisters, Vierstra believes it extended their lives; for him, it may have stopped the disease in its tracks.
A Blueprint for a Liveable Disease
The implications of Vierstra’s case extend far beyond one family. If genetic silencing can prevent the onset of ALS in known carriers, it transforms the disease from an inevitable death sentence into a manageable condition.
Dr. Shneider believes this approach represents a paradigm shift in neurology. “I think there’s real hope and opportunity to make this a liveable disease, one that isn’t fatal,” he said.
The research is now expanding through the “Silence ALS” initiative. This program aims to develop individualized, gene-based therapies for patients with other rare genetic forms of the disease, moving toward a model of precision medicine where the treatment is tailored to the specific mutation of the patient.
For Vierstra, the medical success has translated into a psychological liberation. He continues to perform as a scientist and pursue his passion for extreme sports, feeling as though he has been granted a second chance.
“And maybe this actually is working for me and I can start thinking about the future, and I otherwise couldn’t have,” Vierstra said.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Experimental treatments should only be pursued under the supervision of qualified healthcare providers in a clinical trial setting.
The team at Columbia University continues to monitor Vierstra’s progress and expand the Silence ALS initiative to other rare genetic mutations. Future data from these trials will be critical in determining if prophylactic gene silencing can be standardized for other familial neurodegenerative diseases.
We invite you to share your thoughts on the future of precision medicine in the comments below.
